GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Solid Biosciences Inc (NAS:SLDB) » Definitions » PB Ratio

Solid Biosciences (Solid Biosciences) PB Ratio : 1.42 (As of Apr. 29, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Solid Biosciences PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-29), Solid Biosciences's share price is $8.79. Solid Biosciences's Book Value per Share for the quarter that ended in Dec. 2023 was $6.20. Hence, Solid Biosciences's PB Ratio of today is 1.42.

The historical rank and industry rank for Solid Biosciences's PB Ratio or its related term are showing as below:

SLDB' s PB Ratio Range Over the Past 10 Years
Min: 0.2   Med: 0.58   Max: 2.37
Current: 1.42

During the past 9 years, Solid Biosciences's highest PB Ratio was 2.37. The lowest was 0.20. And the median was 0.58.

SLDB's PB Ratio is ranked better than
69.69% of 1310 companies
in the Biotechnology industry
Industry Median: 2.375 vs SLDB: 1.42

During the past 12 months, Solid Biosciences's average Book Value Per Share Growth Rate was -42.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -35.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -31.40% per year.

During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Solid Biosciences was -18.90% per year. The lowest was -35.70% per year. And the median was -25.40% per year.

Back to Basics: PB Ratio


Solid Biosciences PB Ratio Historical Data

The historical data trend for Solid Biosciences's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solid Biosciences PB Ratio Chart

Solid Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only 2.56 4.87 0.93 0.50 0.99

Solid Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.50 0.64 0.35 0.99

Competitive Comparison of Solid Biosciences's PB Ratio

For the Biotechnology subindustry, Solid Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solid Biosciences's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Solid Biosciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where Solid Biosciences's PB Ratio falls into.



Solid Biosciences PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Solid Biosciences's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=8.79/6.204
=1.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Solid Biosciences  (NAS:SLDB) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Solid Biosciences PB Ratio Related Terms

Thank you for viewing the detailed overview of Solid Biosciences's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Solid Biosciences (Solid Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
500 Rutherford Avenue, Third Floor, Charlestown, MA, USA, 02129
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Executives
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Perceptive Life Sciences Master Fund Ltd director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Kevin Tan officer: CFO & Treasurer 20 HICKORY ROAD, WELLESLEY MA 02482
Ilan Ganot director, officer: Chief Executive Officer C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
David T Howton officer: See Remarks VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Jennifer Marlowe officer: CSO, FA & Cardiac 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Paul Herzich officer: Chief Technology Officer 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Jessie Hanrahan officer: Chief Regulatory Officer 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Gabriel Brooks officer: Chief Medical Officer C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Carl Ashley Morris officer: Chief Scientific Officer C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Georgia Keresty director C/O ASPEN TECHNOLOGY, INC., 20 CROSBY DRIVE, BEDFORD MA 01730
Clare Kahn director 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Ian F Smith director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Bcls Sb Investco, Lp 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Bcls Ii Investo (gp), Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116